---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-25-000060"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:52:39.927941+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026

## Summary
- Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.
- Ratio steps down to 4.75:1 (Sep 2026), 4.50:1 (Dec 2026), and 4.00:1 (Mar 2027 onward).
- No increase in total indebtedness; temporary restrictions on investments, liens, and restricted payments during Covenant Relief Period.
- Amendment effective June 6, 2025, to Seventh Amended and Restated Credit Agreement dated March 24, 2023.
- Company temporarily prohibited from using leverage 'step-up' for permitted acquisitions during Covenant Relief Period.

## SEC filing metadata
- accession: 0000917520-25-000060
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752025000060/0000917520-25-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752025000060/iart-20250606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-25-000060
- JSON: https://secwatch.observer/filing/0000917520-25-000060.json
- Plain text: https://secwatch.observer/filing/0000917520-25-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.